Pain Management Drugs Market Size, Share, Trends, Growth 2032

Pain Management Drugs Industry Prospective:

The global pain management drugs market size was worth around USD 78.66 billion in 2023 and is predicted to grow to around USD 116.90 billion by 2032 with a compound annual growth rate (CAGR) of roughly 4.5% between 2024 and 2032.

Request Free Sample

Request Free Sample

Pain Management Drugs Market: Overview

Pain management drugs are defined as medicine specially created to alleviate or control pain, which is a painful emotional and sensory experience connected to prospective or existing tissue injury. Pain management drugs act on the nervous system to change the perception of pain or to suppress the transmission of pain signals. The pain management drugs market is expected to be driven by several factors including the growing prevalence of chronic diseases, rising product approvals, increasing ageing population, advancements in drug development, rising product launches and many others.

Key Insights

• As per the analysis shared by our research analyst, the global Pain Management Drugs market is estimated to grow annually at a CAGR of around 4.5% over the forecast period (2024-2032).
• In terms of revenue, the global Pain Management Drugs market size was valued at around USD 78.66 billion in 2023 and is projected to reach USD 116.90 billion, by 2032.
• The growing drug approvals are expected to drive market growth during the forecast period.
• Based on the drug class, the Opioids segment is expected to capture the prominent market share during the forecast period.
• Based on the indication, the arthritic pain segment is expected to grow at the fastest rate during the forecast period.
• Based on the pain type, the chronic pain segment is expected to grow at a rapid rate over the forecast period.
• Based on region, North America is expected to hold a prominent market share during the forecast period.

Pain Management Drugs Market: Growth Drivers

The rising incidence of chronic disease drives market growth

The increasing incidence of chronic diseases including cancer, diabetes, cardiovascular disease and others drives the pain management drugs market during the forecast period. These diseases cause chronic pain, which might need pain management drugs to control the pain in the body.

According to the study published by the National Center for Biotechnology Information:

• In India, the incidence of cancer was found 14,61,427 in 2022.
• 1 in 9 people are likely to develop in her lifetime.
• The cancer that was most prevalent in children (0–14 years old) was lymphoid leukemia, which affected males 29.2% of the population at the time and women 24.2%.
• The cases of cancer are estimated to grow by 12.8% in 2025 as compared to 2020.

Thus, the aforementioned statistics are expected to support the pain management drugs industry.

Pain Management Drugs Market: Restraints

Side effects of pain management drugs hampering the market growth

The industry's growth for pain management drugs is anticipated to be hindered throughout the forecast period due to the significant adverse effects of these medications, despite their increasing popularity in the treatment of numerous chronic diseases. The most frequent adverse effects of opioid usage include vomiting, nausea, constipation, and drowsiness. Along with these symptoms, some people may experience difficulty urinating, dizziness, itching, shallow or rapid breathing, and mental consequences including hallucinations, nightmares, or disorientation.

Pain Management Drugs Market: Opportunities

Increasing partnerships among the market players offer a lucrative opportunity for market expansion

The increasing partnership among the market players is expected to offer a lucrative opportunity for the pain management drugs industry during the anticipated timeframe. For instance, in August 2023, Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company, announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

The portfolio includes 13 trademarks in six therapeutic categories, with a primary focus on pain treatment, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be promoted through affiliates in seven key European nations, as well as a network of partners in numerous other areas across the world.

Pain Management Drugs Market: Challenges

Concerns associated with drug abuse pose a major challenge to market growth

The market for pain management drugs is predicted to be hampered due to growing worries about drug abuse and the upcoming expiry of patents on painkilling medicines. Although opioids are frequently used to treat pain, there are serious concerns about abuse, addiction, and the potentially fatal consequences of diversion.

The undertreatment of ailments including cancer pain, end-of-life pain, and acute pain—conditions usually thought to be suitable for opioid therapy—appears to have been exacerbated by worries about addiction. Three million Americans and sixteen million people worldwide suffer from opioid use disorder and are addicted to opioids, according to the National Library of Medicine.

Pain Management Drugs Market: Segmentation

The Global Pain Management Drugs industry is segmented based on the drug class, indication, pain type and region.

Based on the drug class, the global Pain Management Drugs market is bifurcated into Opioids, Anti-migraine Agents, NSAIDs, Anesthetics, Anticonvulsants, Antidepressants and Nonnarcotic Analgesics. The Opioids segment is expected to capture the prominent market share during the forecast period. A family of medications known as opioids is derived from or imitates natural chemicals present in the opium poppy plant. Opioids have several impacts on the brain, one of which is the reduction of pain. Opioids are used or prescribed by physicians to relax the body and relieve the symptoms of an ailment. They are used for an injury or a surgical procedure including post-surgical pain, severe pain due to trauma or disease, coughing and diarrhea. Thus, these applications of opioids drive the segment expansion over the analysis period.

Based on the indication, the global Pain Management Drugs industry is categorized into Postoperative Pain, Neuropathic Pain, Arthritic Pain, Cancer Pain, Chronic Back Pain, Migraine, Fibromyalgia, Muscle sprain/strain, Bone fracture, Acute appendicitis and Others. The arthritic pain segment is expected to grow at the fastest rate during the forecast period owing to the rising prevalence of arthritic pain among individuals. According to the National Health Interview Survey (NHIS), the unadjusted prevalence of arthritis diagnosed by a doctor in the United States from 2019 to 2021 was 17.9% for men and 24.2% for women. Thereby, driving the segment growth.

Based on the pain type, the global Pain Management Drugs market is categorized into Chronic pain and Acute pain. The chronic pain segment is expected to grow at a rapid rate over the forecast period. The growth of the chronic pain segment is owing to the rising prevalence of chronic diseases such as diabetes, CVD and others. As per the data published by the World Health Organization, about 17.9 million people die every year due to cardiovascular disease, accounting for the leading cause of death globally.

Pain Management Drugs Market: Report Scope

Regional Analysis

North America holds the prominent market share in the pain management drugs industry

North America is expected to hold a prominent market share over the forecast period. The growth of the pain management drugs industry in the region is attributed to the presence of major players including Pfizer, Abbott, Boston Scientific Corporation and others. These players consistently invest in research and development to launch innovative products in the market. For instance, in October 2023, Pfizer Inc. received FDA approval for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for individuals with moderately to severely active ulcerative colitis (UC). The authorized recommended dosage of VELSIPITY is 2 mg.

Additionally, the rising prevalence of chronic diseases in the US such as diabetes, CVD, cancer and others also drives the market expansion. According to the Diabetes Research Institute, diabetes affects 37.3 million individuals in the United States, accounting for 11.3% of the population. An estimated 28.7 million persons were diagnosed with diabetes. Approximately 8.6 million individuals have diabetes but have yet to be diagnosed. Thus, the aforementioned statistics are expected to propel the pain management drugs market during the forecast period.

Pain Management Drugs Market: Competitive Analysis

The global Pain Management Drugs market is dominated by players like:

• Grünenthal
• Lilly
• WEX Pharmaceuticals Inc.
• Rusan Pharma
• Vertex Pharmaceuticals Incorporated
• Virpax® Pharmaceuticals
• Neumentum Inc.
• Boston Scientific Corporation
• Averitas Pharma Inc.
• Novaremed
• Bayer AG
• Teikoku Pharma
• Abbott
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• BD

The global Pain Management Drugs market is segmented as follows:

By Drug Class

• Opioids
• Anti-migraine Agents
• NSAIDs
• Anesthetics
• Anticonvulsants
• Antidepressants
• Nonnarcotic Analgesics

By Indication

• Postoperative Pain
• Neuropathic Pain
• Arthritic Pain
• Cancer Pain
• Chronic Back Pain
• Migraine
• Fibromyalgia
• Muscle sprain/strain
• Bone fracture
• Acute appendicitis
• Others

By Pain Type

• Chronic Pain
• Acute Pain

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa